The closing price of Atara Biotherapeutics Inc (NASDAQ: ATRA) was $0.76 for the day, up 9.36% from the previous closing price of $0.70. In other words, the price has increased by $+0.0652 from its previous closing price. On the day, 11169086 shares were traded.
Ratios:
Our analysis of ATRA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.42 and its Current Ratio is at 1.50.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Mizuho on November 09, 2023, Downgraded its rating to Neutral and sets its target price to $1 from $31 previously.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 04 ’24 when Touchon Pascal sold 24,844 shares for $0.72 per share. The transaction valued at 17,888 led to the insider holds 1,910,652 shares of the business.
Nguyen AnhCo sold 10,746 shares of ATRA for $7,737 on Mar 04 ’24. The EVP, Chief Sci. & Tech Officer now owns 941,397 shares after completing the transaction at $0.72 per share. On Mar 04 ’24, another insider, Murugan Amar, who serves as the EVP, Chief Legal Officer of the company, sold 10,044 shares for $0.72 each. As a result, the insider received 7,232 and left with 727,521 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ATRA now has a Market Capitalization of 77.61M and an Enterprise Value of 37.01M. For the stock, the TTM Price-to-Sale (P/S) ratio is 21.67. Its current Enterprise Value per Revenue stands at 8.15 whereas that against EBITDA is -0.11.
Stock Price History:
Over the past 52 weeks, ATRA has reached a high of $3.43, while it has fallen to a 52-week low of $0.20. The 50-Day Moving Average of the stock is 0.7103, while the 200-Day Moving Average is calculated to be 1.2667.
Shares Statistics:
ATRA traded an average of 3.56M shares per day over the past three months and 2.96M shares per day over the past ten days. A total of 129.19M shares are outstanding, with a floating share count of 117.42M. Insiders hold about 9.11% of the company’s shares, while institutions hold 51.41% stake in the company. Shares short for ATRA as of Feb 15, 2024 were 10.87M with a Short Ratio of 3.05, compared to 7.33M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 10.67% and a Short% of Float of 10.94%.
Earnings Estimates
The firm’s stock currently is rated by 5 analysts. On average, analysts expect EPS of -$0.48 for the current quarter, with a high estimate of -$0.31 and a low estimate of -$0.62, while EPS last year was -$0.72. The consensus estimate for the next quarter is -$0.47, with high estimates of -$0.26 and low estimates of -$0.62.
Analysts are recommending an EPS of between -$2.37 and -$2.67 for the fiscal current year, implying an average EPS of -$2.54. EPS for the following year is -$1.48, with 5 analysts recommending between -$0.5 and -$2.5.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 6 analysts. It ranges from a high estimate of $30M to a low estimate of $2M. As of the current estimate, Atara Biotherapeutics Inc’s year-ago sales were $221k, an estimated increase of 5,126.20% from the year-ago figure.
A total of 6 analysts have provided revenue estimates for ATRA’s current fiscal year. The highest revenue estimate was $32.3M, while the lowest revenue estimate was $6M, resulting in an average revenue estimate of $15.42M. In the same quarter a year ago, actual revenue was $63.57M, down -75.70% from the average estimate.
